Acute Myeloid Leukemia (AML)

GTB-3550 TriKE Stimulates Natural Killer Cell Function in MDS and AML

Original Publication Date
Article Source
External Web Content
December 5, 2020 - GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia. GTB-3550 TriKE was found to safely drive natural killer cell proliferation in patients with high-risk…

Oral Azacitidine Improves, Sustains Health-Related QoL in AML

Original Publication Date
Article Source
External Web Content
Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial. Treatment with oral azacitidine (CC-486) showed sustained health-related quality…

Significant Racial, Ethnic Related Socioeconomic Disparities Influence Survival in AML

Original Publication Date
Article Source
External Web Content
Census tract socioeconomic status information demonstrated significant disparities between survival outcomes of non-Hispanic white, non-Hispanic black, and Hispanic patients with acute myeloid leukemia AML in the Chicago metropolitan area. Significant disparities were found…

Beat AML Master Clinical Trial Showcases Paradigm Shift With Precision Medicine

Original Publication Date
Article Source
External Web Content
Delaying treatment for up to 7 days so that genomic data can be utilized to inform a personalized treatment approach is safe, feasible, and can improve overall survival in patients with acute myeloid leukemia. John C. Byrd, MD Delaying treatment for up to 7 days so that genomic…

Aditi Shastri, M.B.B.S.

Institution
Albert Einstein College of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
About
Dr. Aditi Shastri, M.B.B.S. is a Hematologist/Oncologist at Montefiore Medical Center and is an Assistant Professor at the Albert Einstein College of Medicine. Dr. Shastri earned her medical degree from Lokmanya Tilak Municipal Medical College and is an experienced clinical researcher in the areas of acute myeloid leukemia, myelodysplastic syndromes, cancer stem cells, transcription factors, STAT3, RNA biology and therapeutic interference and health disparities.

Alice S. Mims, MD

Institution
Ohio State University Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Dr. Alice S. Mims is the Acute Leukemia Clinical Research Director and Associate Professor in the Division of Hematology at Ohio State University Comprehensive Cancer Center - James. Dr. Mims is a hematologist who specializes in treating patients with acute and chronic myeloid diseases, particularly AML, She earned her medical degree and Masters of Science in Clinical Research (MSCR) from the Medical University of South Carolina. Her research focuses on studying the effectiveness of novel therapeutics on patients with AML and other myeloid neoplasms including MDS. She is currently the lead

David Jacobsohn, MD, ScM

Institution
Children's National
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
Pediatric
About
David Jacobsohn, MD, ScM is the Division Chief, Blood and Marrow Transplanation at Children's National Hospital in Washington, D.C. Previously, he was at Children’s Memorial Hospital in Chicago, where he served as a member of the Stem Cell Transplant Program staff and as the Director of the Chronic Graft-versus-Host Disease Clinic. He has lectured widely on GvHD/BMT in Europe, Latin America, and the United States. Dr. Jacobsohn obtained a Bachelor of Science from Yale University, his medical degree from Tufts University, and a Masters in Clinical Investigation from Johns Hopkins School of

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Treatment Approaches in AML: Key Testing for Personalized Care

Original Publication Date
Article Source
External Web Content
VIDEO Description: Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo. When it comes to Acute Myeloid Leukemia (AML), genetic testing (or biomarker testing) is essential in helping to determine the best treatment approach for…
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.